Suven Pharmaceuticals (BOM:543064) Interest Expense : ₹-75 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Suven Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Suven Pharmaceuticals's interest expense for the three months ended in Mar. 2024 was ₹ -45 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was ₹-75 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Suven Pharmaceuticals's Operating Income for the three months ended in Mar. 2024 was ₹ 583 Mil. Suven Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was ₹ -45 Mil. Suven Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 was 12.87. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Suven Pharmaceuticals Interest Expense Historical Data

The historical data trend for Suven Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suven Pharmaceuticals Interest Expense Chart

Suven Pharmaceuticals Annual Data

Trend

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Interest Expense

Get a 7-Day Free Trial

-199.15

-91.44

-62.31

-128.11

-74.51

Suven Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-96.83	-11.47	-5.03	-12.69	-45.33

Suven Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-75 Mil.

Suven Pharmaceuticals (BOM:543064) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Suven Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was ₹-45 Mil. Its Operating Income for the three months ended in Mar. 2024 was ₹583 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was ₹212 Mil.

Suven Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	583.311	/	-45.328
	=	12.87

The higher the ratio, the stronger the company's financial strength is.

Suven Pharmaceuticals (BOM:543064) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suven Pharmaceuticals Ltd (BOM:543064) » Definitions » Interest Expense

Traded in Other Exchanges

SUVENPHAR:India

Address

3rd Floor, Road No. 5, Avenue 7, Banjara Hills, No. 8-2-334, SDE Serene Chambers, Hyderabad, TG, IND, 500034

Website

https://www.suvenpharm.com

Suven Pharmaceuticals Ltd is engaged in the development and manufacturing of Intermediates, Active Pharmaceutical Ingredients (API), specialty chemicals and formulated drugs under Contract Research and Manufacturing Services (CRAMS) for global pharmaceutical, biotechnology and chemical companies. The company has single operating segment that is Pharmaceuticals Manufacturing & Services and its geographical segments include India; the USA; Europe and the Rest of the World. The company derives a majority of revenue from the Europe segment.

Suven Pharmaceuticals (BOM:543064) Headlines

No Headlines